186 related articles for article (PubMed ID: 22661489)
1. Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study a5199, the International Neurological Study.
Robertson K; Jiang H; Kumwenda J; Supparatpinyo K; Evans S; Campbell TB; Price R; Tripathy S; Kumarasamy N; La Rosa A; Santos B; ; Silva MT; Montano S; Kanyama C; Faesen S; Murphy R; Hall C; Marra CM; Marcus C; Berzins B; Allen R; Housseinipour M; Amod F; Sanne I; Hakim J; Walawander A; Nair A;
Clin Infect Dis; 2012 Sep; 55(6):868-76. PubMed ID: 22661489
[TBL] [Abstract][Full Text] [Related]
2. Human Immunodeficiency Virus-associated Neurocognitive Impairment in Diverse Resource-limited Settings.
Robertson KR; Jiang H; Kumwenda J; Supparatpinyo K; Marra CM; Berzins B; Hakim J; Sacktor N; Campbell TB; Schouten J; Mollan K; Tripathy S; Kumarasamy N; La Rosa A; Santos B; Silva MT; Kanyama C; Firhnhaber C; Murphy R; Hall C; Marcus C; Naini L; Masih R; Hosseinipour MC; Mngqibisa R; Badal-Faesen S; Yosief S; Vecchio A; Nair A;
Clin Infect Dis; 2019 May; 68(10):1733-1738. PubMed ID: 30219843
[TBL] [Abstract][Full Text] [Related]
3. Change in vitamin d levels occurs early after antiretroviral therapy initiation and depends on treatment regimen in resource-limited settings.
Havers FP; Detrick B; Cardoso SW; Berendes S; Lama JR; Sugandhavesa P; Mwelase NH; Campbell TB; Gupta A;
PLoS One; 2014; 9(4):e95164. PubMed ID: 24752177
[TBL] [Abstract][Full Text] [Related]
4. Human Immunodeficiency Virus Type 1 and Tuberculosis Coinfection in Multinational, Resource-limited Settings: Increased Neurological Dysfunction.
Robertson KR; Oladeji B; Jiang H; Kumwenda J; Supparatpinyo K; Campbell TB; Hakim J; Tripathy S; Hosseinipour MC; Marra CM; Kumarasamy N; Evans S; Vecchio A; La Rosa A; Santos B; Silva MT; Montano S; Kanyama C; Firnhaber C; Price R; Marcus C; Berzins B; Masih R; Lalloo U; Sanne I; Yosief S; Walawander A; Nair A; Sacktor N; Hall C;
Clin Infect Dis; 2019 May; 68(10):1739-1746. PubMed ID: 30137250
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings.
Campbell TB; Smeaton LM; Kumarasamy N; Flanigan T; Klingman KL; Firnhaber C; Grinsztejn B; Hosseinipour MC; Kumwenda J; Lalloo U; Riviere C; Sanchez J; Melo M; Supparatpinyo K; Tripathy S; Martinez AI; Nair A; Walawander A; Moran L; Chen Y; Snowden W; Rooney JF; Uy J; Schooley RT; De Gruttola V; Hakim JG;
PLoS Med; 2012; 9(8):e1001290. PubMed ID: 22936892
[TBL] [Abstract][Full Text] [Related]
6. A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa.
; Ratsela A; Polis M; Dhlomo S; Emery S; Grandits G; Khabo P; Khanyile T; Komati S; Neaton JD; Naidoo LC; Magongoa D; Qolohle D
J Infect Dis; 2010 Nov; 202(10):1529-37. PubMed ID: 20942650
[TBL] [Abstract][Full Text] [Related]
7. International neurocognitive normative study: neurocognitive comparison data in diverse resource-limited settings: AIDS Clinical Trials Group A5271.
Robertson K; Jiang H; Evans SR; Marra CM; Berzins B; Hakim J; Sacktor N; Silva MT; Campbell TB; Nair A; Schouten J; ; Kumwenda J; Supparatpinyo K; Tripathy S; Kumarasamy N; la Rosa A; Montano S; Mwafongo A; Firnhaber C; Sanne I; Naini L; Amod F; Walawander A;
J Neurovirol; 2016 Aug; 22(4):472-8. PubMed ID: 26733457
[TBL] [Abstract][Full Text] [Related]
8. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
Gallant JE; DeJesus E; Arribas JR; Pozniak AL; Gazzard B; Campo RE; Lu B; McColl D; Chuck S; Enejosa J; Toole JJ; Cheng AK;
N Engl J Med; 2006 Jan; 354(3):251-60. PubMed ID: 16421366
[TBL] [Abstract][Full Text] [Related]
9. Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV-1-Infected Patients Starting Efavirenz, Lopinavir-Ritonavir, or Atazanavir-Ritonavir Plus Tenofovir/Emtricitabine: Final 48-Week Results (The Advanz-3 Trial).
Miro JM; Manzardo C; Ferrer E; Loncà M; Guardo AC; Podzamczer D; Domingo P; Curran A; Clotet B; Cruceta A; Lozano F; Pérez I; Plana M; Gatell JM;
J Acquir Immune Defic Syndr; 2015 Jun; 69(2):206-15. PubMed ID: 25831464
[TBL] [Abstract][Full Text] [Related]
10. Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review.
Cysique LA; Brew BJ
Neuropsychol Rev; 2009 Jun; 19(2):169-85. PubMed ID: 19424802
[TBL] [Abstract][Full Text] [Related]
11. Increased virological failure in naive HIV-1-infected patients taking lamivudine compared with emtricitabine in combination with tenofovir and efavirenz or nevirapine in the Dutch nationwide ATHENA cohort.
Rokx C; Fibriani A; van de Vijver DA; Verbon A; Schutten M; Gras L; Rijnders BJ;
Clin Infect Dis; 2015 Jan; 60(1):143-53. PubMed ID: 25273080
[TBL] [Abstract][Full Text] [Related]
12. Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study.
Winston A; Duncombe C; Li PC; Gill JM; Kerr SJ; Puls R; Petoumenos K; Taylor-Robinson SD; Emery S; Cooper DA;
Clin Infect Dis; 2010 Mar; 50(6):920-9. PubMed ID: 20146627
[TBL] [Abstract][Full Text] [Related]
13. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
[TBL] [Abstract][Full Text] [Related]
14. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort.
Robertson KR; Su Z; Margolis DM; Krambrink A; Havlir DV; Evans S; Skiest DJ;
Neurology; 2010 Apr; 74(16):1260-6. PubMed ID: 20237308
[TBL] [Abstract][Full Text] [Related]
15. Predicting HIV disease progression in children using measures of neuropsychological and neurological functioning. Pediatric AIDS clinical trials 152 study team.
Pearson DA; McGrath NM; Nozyce M; Nichols SL; Raskino C; Brouwers P; Lifschitz MC; Baker CJ; Englund JA
Pediatrics; 2000 Dec; 106(6):E76. PubMed ID: 11099619
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342).
Castillo-Mancilla JR; Aquilante CL; Wempe MF; Smeaton LM; Firnhaber C; LaRosa AM; Kumarasamy N; Andrade A; Baheti G; Fletcher CV; Campbell TB; Haas DW; MaWhinney S; Anderson PL
J Antimicrob Chemother; 2016 Jun; 71(6):1609-18. PubMed ID: 26892777
[TBL] [Abstract][Full Text] [Related]
17. A multinational study of neurological performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settings.
Robertson K; Kumwenda J; Supparatpinyo K; Jiang JH; Evans S; Campbell TB; Price RW; Murphy R; Hall C; Marra CM; Marcus C; Berzins B; Masih R; Santos B; Silva MT; Kumarasamy N; Walawander A; Nair A; Tripathy S; Kanyama C; Hosseinipour M; Montano S; La Rosa A; Amod F; Sanne I; Firnhaber C; Hakim J; Brouwers P;
J Neurovirol; 2011 Oct; 17(5):438-47. PubMed ID: 21786076
[TBL] [Abstract][Full Text] [Related]
18. Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202.
McComsey GA; Kitch D; Sax PE; Tierney C; Jahed NC; Melbourne K; Ha B; Brown TT; Bloom A; Fedarko N; Daar ES
J Acquir Immune Defic Syndr; 2014 Feb; 65(2):167-74. PubMed ID: 24121755
[TBL] [Abstract][Full Text] [Related]
19. Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial.
Krown SE; Moser CB; MacPhail P; Matining RM; Godfrey C; Caruso SR; Hosseinipour MC; Samaneka W; Nyirenda M; Busakhala NW; Okuku FM; Kosgei J; Hoagland B; Mwelase N; Oliver VO; Burger H; Mngqibisa R; Nokta M; Campbell TB; Borok MZ;
Lancet; 2020 Apr; 395(10231):1195-1207. PubMed ID: 32145827
[TBL] [Abstract][Full Text] [Related]
20. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
Cahn P; Madero JS; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man C; Currie A; Underwood M; Tenorio AR; Pappa K; Wynne B; Fettiplace A; Gartland M; Aboud M; Smith K;
Lancet; 2019 Jan; 393(10167):143-155. PubMed ID: 30420123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
